Effect of alendronate on bone remodeling around implant in the rat

키워드

참고문헌 (37)

1. Drake MT, "Bisphosphonates: mechanism of action and role in clinical practice", Mayo Clin Proc, 83, pp.1032~1045 (2008)
2. Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
3. Ruggiero SL, "Osteonecrosis of the jaws associated with the use of bisphosphonates:a review of 63 cases", J Oral Maxillofac Surg, 62, pp.527~534 (2004)
4. Allen MR, "The pathogenesis of bisphosphonaterelated osteonecrosis of the jaw: so many hypotheses, so few data", J Oral Maxillofac Surg, 67, pp.61~70 (2009)
5. Hikita H, "Bisphosphonate administration prior to tooth extraction delays initial healing of the extraction socket in rats", J Bone Miner Metab, 27, pp.663~672 (2009)
6. Kobayashi Y, "Zoledronic acid delays wound healing of the tooth extraction socket, inhibits oral epithelial cell migration, and promotes proliferation and adhesion to hydroxyapatite of oral bacteria, without causing osteonecrosis of the jaw, in mice", J Bone Miner Metab, 28, pp.165~175 (2010)
7. Lazarovici TS, "Bisphosphonate-related osteonecrosis of the jaw associated with dental implants", J Oral Maxillofac Surg, 68, pp.790~796 (2010)
8. Grant BT, "Outcomes of placing dental implants in patients taking oral bisphosphonates:a review of 115 cases", J Oral Maxillofac Surg, 66, pp.223~230 (2008)
9. Smith SY, "Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys", Bone, 32, pp.45~55 (2003)
10. Allen MR, "Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs", J Bone Miner Res, 25, pp.98~105 (2010)
11. Ruggiero SL, "Osteonecrosis of the jaws and bisphosphonate therapy", J Dent Res, 86, pp.1013~1021 (2007)
12. Futami T, "Tissue response to titanium implants in the rat maxilla: ultrastructural and histochemical observations of the bone-titanium interface", J Periodontol, 71, pp.287~298 (2000)
13. Listgarten MA, "Soft and hard tissue response to endosseous dental implants", Anat Rec, 245, pp.410~425 (1996)
14. Masuda T, "Generalizations regarding the process and phenomenon of osseointegration. Part I. In vivo studies", Int J Oral Maxillofac Implants, 13, pp.17~29 (1998)
15. Pereira MC, "Ovariectomy delays alveolar wound healing after molar extractions in rats", J Oral Maxillofac Surg, 65, pp.2248~2253 (2007)
16. Fujii N, "A histological study on tissue responses to titanium implantation in rat maxilla: the process of epithelial regeneration and bone reaction", J Periodontol, 69, pp.485~495 (1998)
17. Karimbux NY, "A new animal model for molecular biological analysis of the implant-tissue interface: spatial expression of type XII collagen mRNA around a titanium oral implant", J Oral Implantol, 21, pp.107~113 (1995)
18. Shimizu M, "Bone wound healing after maxillary molar extraction in ovariectomized aged rats", J Electron Microsc, 47, pp.517~526 (1998)
19. Bi Y, "Bisphosphonates cause osteonecrosis of the jawlike disease in mice", Am J Pathol, 177, pp.280~290 (2010)
20. Kikuiri T, "Cell-based immuno-therapy with mesenchymal stem cells cures bisphosphonaterelated osteonecrosis of the jaw-like disease in mice", J Bone Miner Res, 25, pp.1668~1679 (2010)
21. Mashiba T, "Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures", Bone, 29, pp.271~278 (2001)
22. Mashiba T, "Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles", Bone, 28, pp.524~531 (2001)
23. Whyte MP, "Bisphosphonate-induced osteopetrosis", N Engl J Med, 349, pp.457~463 (2003)
24. Odvina CV, "Severely suppressed bone turnover: a potential complication of alendronate therapy", J Clin Endocrinol Metab, 90, pp.1294~1301 (2005)
25. Visekruna M, "Severely suppressed bone turnover and atypical skeletal fragility", J Clin Endocrinol Metab, 93, pp.2948~2952 (2008)
26. Rogers MJ, "Cellular and molecular mechanisms of action of bisphosphonates", Cancer, 88, pp.2961~2978 (2000)
27. Russell RG, "Bisphosphonates: mode of action and pharmacology", Pediatrics, 119, pp.150~162 (2007)
28. Fleisch H, "Bisphosphonates: mechanisms of action", Endocr Rev, 19, pp.80~100 (1998)
29. Balena R, "The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates", J Clin Invest, 92, pp.2577~2586 (1993)
30. Chavassieux PM, "Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis", J Clin Invest, 100, pp.1475~1480 (1997)
31. Yang Li C, "High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse", Bone, 37, pp.287~295 (2005)
32. Weinstein RS, "Giant osteoclast formation and long-term oral bisphosphonate therapy", N Engl J Med, 360, pp.53~62 (2009)
33. Hauge EM, "Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers", J Bone Miner Res, 16, pp.1575~1582 (2001)
34. Hirao M, "Response of serum carboxylated and undercarboxylated osteocalcin to alendronate monotherapy and combined therapy with vitamin K2 in postmenopausal women", J Bone Miner Metab, 26, pp.260~264 (2008)
35. Wood J, "Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid", J Pharmacol Exp Ther, 302, pp.1055~1061 (2002)
36. Rubin CT, "Suppression of the osteogenic response in the aging skeleton", Calcif Tissue Int, 50, pp.306~313 (1992)
37. Klein-Nulend J, "Donor age and mechanosensitivity of human bone cells", Osteoporos Int, 13, pp.137~146 (2002)

관련 논문AI추천